InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
0.6653
-0.0050 (-0.75%)
At close: Apr 2, 2026, 4:00 PM EDT
0.6780
+0.0127 (1.91%)
After-hours: Apr 2, 2026, 4:04 PM EDT
InMed Pharmaceuticals Revenue
InMed Pharmaceuticals had revenue of $820.19K in the quarter ending December 31, 2025, a decrease of -26.22%. This brings the company's revenue in the last twelve months to $4.51M, down -6.73% year-over-year. In the fiscal year ending June 30, 2025, InMed Pharmaceuticals had annual revenue of $4.94M with 7.50% growth.
Revenue (ttm)
$4.51M
Revenue Growth
-6.73%
P/S Ratio
0.61
Revenue / Employee
$346,661
Employees
13
Market Cap
2.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.94M | 344.90K | 7.50% |
| Jun 30, 2024 | 4.60M | 462.17K | 11.18% |
| Jun 30, 2023 | 4.14M | 3.05M | 279.61% |
| Jun 30, 2022 | 1.09M | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IM Cannabis | 39.92M |
| Sunshine Biopharma | 37.32M |
| Universe Pharmaceuticals INC | 17.86M |
| Sonoma Pharmaceuticals | 17.72M |
| RedHill Biopharma | 9.55M |
| China Pharma Holdings | 4.05M |
| China SXT Pharmaceuticals | 1.54M |
| Akanda | 836.66K |
INM News
- 7 days ago - InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Newsfile Corp
- 11 days ago - InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Newsfile Corp
- 25 days ago - InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial - Newsfile Corp
- 4 weeks ago - InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Newsfile Corp
- 7 weeks ago - InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update - Newsfile Corp
- 3 months ago - InMed Announces Results of 2025 Annual General and Special Meeting - Newsfile Corp
- 4 months ago - InMed Provides Update on BayMedica Commercial Business - Newsfile Corp
- 4 months ago - InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 - Newsfile Corp